2026년 2월 24일 · Unknown · financial · 출처 Yahoo Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Axsome Therapeutics has seen its modeled fair value edge from US$215.44 to about US$216.09, a small adjustment that still matters if you are tracking the stock closely. This aligns with recent analyst work that has pushed price targets into a US$193 to US$248 range, as firms revisit their views on the company’s portfolio and pipeline. As you read on, you will see what is driving these updates and how you can keep up with the evolving Axsome story.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Axsome Therapeutics.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
Several firms have raised their modeled value for Axsome Therapeutics, with Wells Fargo moving its price target to US$193 from US$157 after Q4 2025 Auvelity and Sunosi sales came in above consensus and the FDA granted priority review for ADA. UBS lifted its target to US$248 from US$163 and kept a Buy rating, pointing to a generally constructive setup for biotech and highlighting potential support from M&A capital in the sector. Baird increased its target to US$209 from US$157, updating its model after preliminary Q4 results that it described as a slight beat. Mizuho most recently raised its target to US$230 from US$217 and maintained an Outperform rating, signaling continued confidence in the Axsome story at higher valuation levels.
🐻 Bearish Takeaways
While targets have moved higher, commentary from firms like UBS also reminds you that broader biotech funding trends, including secondary offerings and IPO activity, can influence how quickly Street expectations are reflected in share prices.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGM:AXSM 1-Year Stock Price Chart
See how Axsome Therapeutics' fair value stacks up across multiple valuation models — not just analyst targets.
What's in the News
Axsome reached a settlement with Alkem Laboratories over Sunosi patents, giving Alkem a license to sell a generic version in the US from March 1, 2040 or September 1, 2040, depending on pediatric exclusivity, subject to FDA approval and regulatory review. The company dosed the first patient in the FORWARD Phase 3 trial of AXS-14 for fibromyalgia, using a randomized withdrawal design with an initial 12 week open label period followed by a double blind phase versus placebo. Axsome received formal pre NDA meeting minutes from the FDA indicating its data package is sufficient to support an NDA submission for AXS-12 for cataplexy in narcolepsy, with Orphan Drug Designation that may allow seven years of US marketing exclusivity and a waiver of FDA user fees upon approval. The company issued preliminary unaudited guidance for total product revenue of about US$196.0 million for Q4 2025 and about US$638.5 million for full year 2025, which the company described as 65% and 66% annual growth versus Q4 2024 and full year 2024.
Story Continues
How This Changes the Fair Value For Axsome Therapeutics
The fair value in the model moves from US$215.44 to about US$216.09 per share. The revenue growth assumption shifts from 51.94% to about 51.91%. The net profit margin estimate adjusts from 33.81% to about 33.97%. The future P/E multiple changes from 21.80x to about 21.37x. The discount rate remains at 6.98% with no change to the assumed risk level.
Never Miss an Update: Follow The Narrative
Narratives connect Axsome Therapeutics' business story to a set of concrete forecasts and assumptions, so you can see how product launches, trials, and risks feed into a fair value view. They refresh as new data, guidance, and clinical news come through.
Head over to the Simply Wall St Community and follow the Narrative on Axsome Therapeutics to stay up to date on:
How a growing CNS portfolio around Auvelity, Sunosi, SYMBRAVO, AXS-12, and AXS-14 could reduce reliance on any single product and broaden Axsome's revenue base. What wider payer coverage, formulary wins, and commercial investment might mean for product adoption, operating leverage, and long term margin goals. The key risks around high SG&A spend, pricing and reimbursement pressure, intense competition in CNS, ongoing net losses, and potential dilution if funding needs increase.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AXSM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments